

sponded but subsequently progressed. A biopsy was then performed, with pathology consistent with infiltrating piloid astrocytoma with anaplastic features (elevated mitoses and Ki-67 index); a BCAN-NTRK1 fusion was identified by RT-PCR and confirmed by Sanger sequencing. After further disease progression on vinblastine monotherapy, this patient began treatment with entrectinib (NCT02650401), with favorable clinical and radiographic responses thus far. The second patient was diagnosed with a large suprasellar/ optic pathway tumor at 3 years old, and underwent upfront partial resection, revealing similar infiltrating piloid/pilocytic astrocytoma with anaplastic features (elevated mitoses and Ki-67 index). A diagnosis of “midline” infantile high-grade glioma (HGG) was also considered, as with the former case. Sequencing demonstrated a SOX10-NTRK3 rearrangement, resulting in an integrated diagnosis of NTRK-fused infantile HGG, for which the patient recently started treatment with larotrectinib (NCT04655404). Both patients’ fusions retain the entire kinase domain of respective NTRK partners, supporting oncogenicity, and neither tumor harbored additional somatic pathogenic variants (both lacked BRAF alterations). Methylation profiling did not confidently classify either tumor. CONCLUSIONS: NTRK-rearranged gliomas may present with primary suprasellar/ optic pathway involvement in infants. Given the potential to offer targeted therapy, testing for the presence of NTRK fusions should be strongly considered for infantile gliomas in any location, including midline, and across the histologic spectrum.

#### HGG-25. TARGETING KLF5 REDUCES TUMORIGENIC PHENOTYPE IN A MURINE GLIOBLASTOMA (GBM) MODEL

Tamara Abou-Antoun<sup>1</sup>, Najla Kfoury<sup>2</sup>, Lihua Yang<sup>1</sup>, Nicole Warrington<sup>1</sup>, Xuhua Chen<sup>1</sup>, India Reiss<sup>1</sup>, Michael Wilkinson<sup>1</sup>, Robi Mitra<sup>1</sup>, Josh Rubin<sup>1</sup>; <sup>1</sup>Washington University in Saint Louis, Saint Louis, MO, USA. <sup>2</sup>University of California San Diego, San Diego, CA, USA

Sex differences are evident in the incidence, therapeutic response and survival of patients with various cancers including the most common, aggressive and incurable GBM. We generated a murine GBM model of male and female astrocytes with dual loss of NF1 and P53 that yielded a sex-biased transformation of the astrocytes with male cells being significantly more tumorigenic and therapeutically resistant compared to female cells. In our current work, we aimed to delineate the molecular mechanisms driving this sex-biased tumorigenic phenotype in order to deliver therapies that are more effective to patients with GBM. We examined the inhibition of KLF5 on tumorigenic phenotypes using cellular bio-functional assays. We used barcoded transposon calling cards to determine the genomic localization of KLF5 and the differentially induced gene expression in male versus female GBM cells. Chemical inhibition or shRNA knock-down of KLF5 significantly reduced proliferation, migration, clonogenic stem-cell frequency and survival, but increase apoptosis in male and female GBM cells. Interestingly, male, but not female, GBM cells exhibited an increased migratory phenotype after radiation that inhibition of KLF5 significantly reduced. Moreover, KLF5 inhibition significantly reduced the protein expression of tumorigenic PDGFRB, AKT, ERK and the stem marker Sox-2. Transposon calling cards mapped unique KLF5 genomic localization in male versus female GBM cells with significantly differential gene expression profiles between the two. The top genes induced by KLF5 in male cells were primarily affiliated with poorer prognosis and reduced survival, whereas in female cells they were affiliated with better prognosis and improved survival in patients with cancer. Our findings provide a promising exploratory avenue for KLF5 as a therapeutic target in GBM and warrants further investigation in order to delineate the precise molecular mechanisms driving this antitumor response so that targeted therapy would be more effective taking into consideration the sex-differences in patients with GBM.

#### HGG-26. COMPREHENSIVE GENOMIC PROFILING OF PEDIATRIC AND AYA HIGH-GRADE GLIOMAS REVEALS A HIGH PREVALENCE OF ATRX AND HOMOLOGOUS RECOMBINATION REPAIR (HRR) MUTATIONS

Zheng Kuang<sup>1</sup>, Matthew Hiemenz<sup>1</sup>, Michael Angelo Huang<sup>2,3</sup>; <sup>1</sup>Foundation Medicine, Brookline, MA, USA. <sup>2</sup>Norton Children's Cancer Institute, Louisville, KY, USA. <sup>3</sup>University of Louisville, Louisville, KY, USA

BACKGROUND: Pediatric high-grade glioma (HGG) is a devastating heterogeneous disease with a clear need for more effective treatment options. Advances in high-throughput molecular sequencing have advanced our understanding of these tumors and yet outcomes remain poor as only a very small subset of patients have demonstrated benefit from targeted therapy approaches. METHODS: We compiled genomic data from 980 pediatric (N=400) and AYA (18 to 30 yrs, N=580) HGG cases that underwent targeted, panel-based comprehensive genomic profiling (FoundationOne® CDx). RESULTS: Among pediatric patients, mutations in ATRX or HRR-related genes were among the most prevalent at 24.25% and 19.5%, respectively. Other commonly occurring mutations were seen in TP53 (58.25%), H3F3A (43%), and PIK3CA/PIK3R1 (22%). Among AYA patients, mutations in

ATRX and HRR-related genes were seen in 51.72% and 17.24% of cases, respectively. The most common mutations seen in this older population were in TP53 (76.38%), IDH1/2 (50.86%), PIK3CA/PIK3R1 (20.52%), and H3F3A (18.28%). Among patients with diffuse midline glioma (harboring H3K27M mutations), ATRX and HRR mutations were reported in 21.27% and 13.57% of cases, respectively. Among pediatric patients with histone wild type HGG, mutations in ATRX and HRR-related genes occurred in 20.61% and 21.05% of cases, respectively. CONCLUSION: Alterations in ATRX and HRR-related genes are among the most prevalent mutations in pediatric and AYA HGG. Consideration should be made towards the development of subtype-specific treatment protocols using PARP and/or ATR inhibitors aimed at this subgroup of patients.

#### HGG-27. UNDERSTANDING THE ROLE OF PLAG FAMILY TRANSCRIPTION FACTORS IN CORTEX DEVELOPMENT AND TUMORIGENESIS

Jan Vaillant<sup>1,2</sup>, Nina Hofmann<sup>1</sup>, Michaela-Kristina Keck<sup>1</sup>, David T.W. Jones<sup>1</sup>, Lena M. Kutscher<sup>1</sup>, Stefan M. Pfister<sup>1,3</sup>; <sup>1</sup>Hopp-Children's Cancer Center Heidelberg (KITZ) and German Cancer Research Center (DKFZ), Heidelberg, Germany. <sup>2</sup>Faculty of Biosciences, Heidelberg University, Heidelberg, Germany. <sup>3</sup>Heidelberg University Hospital, Department of Pediatric Hematology and Oncology, Heidelberg, Germany

Gliomas are the most common type of central nervous system (CNS) tumors in children. Therapy and outcome often reflect the grade of the tumor, with high grade glioma (HGG) leading to a significantly worse survival prognosis than low grade glioma. However, HGG are highly diverse regarding their molecular entities and clinical associations. In some pediatric-type histone 3 K27M mutated HGG, the zinc-finger transcription factor PLAG1 was previously found to be overexpressed, which is also confirmed by patient data from the INFORM program. Further, in a novel type of embryonic CNS tumors without histone mutations, the PLAG1-related genes PLAGL1/PLAGL2 are amplified. However, the consequences of aberrant PLAG gene expression on CNS tumor formation during development are unknown. Especially the understanding of downstream signaling pathways that are commonly altered by this transcription factor family could provide necessary starting points for more specific therapy. We use transgenic mouse models with targeted PLAG1 overexpression in neural stem and progenitor cells to investigate the function of PLAG1 in cerebral cortex development and tumorigenesis. We found that PLAG1 overexpression together with heterozygous loss of p53 activity causes neurological defects and impaired cortex development. Next, to understand how PLAG gene overexpression affects neural specification, we will overexpress the PLAG genes in embryonic neural stem and progenitor cells using *in utero* electroporation. After FACS isolation of electroporated cells and single nucleus RNA sequencing, we will assess how the overexpression changes the transcriptional trajectories of neural development in mouse cortex stem and progenitor cells. We hypothesize that an early event leads to the constitutive upregulation of PLAG genes, which are usually tightly regulated during development, in patients with pediatric brain tumors harboring aberrant PLAG gene expression. Deciphering the transcriptional downstream pathways of this aberrant expression in neural stem and progenitor cells seems promising to find new potential therapeutic targets.

#### HGG-28. CLIC1 AND CLIC4 ION CHANNEL DEFICIENCY CONFERS INCREASED SENSITIVITY TO TUMOUR TREATING FIELDS AND IMPROVED SURVIVAL IN PAEDIATRIC GLIOBLASTOMA

Michaela Griffin<sup>1</sup>, Stuart Smith<sup>1,2</sup>, Surajit Basu<sup>3</sup>, Raheela Khan<sup>4</sup>; <sup>1</sup>Childrens Brain Tumour Research Centre, University of Nottingham, Nottingham, United Kingdom. <sup>2</sup>Department of Neurosurgery, Queens Medical Centre, Nottingham, United Kingdom. <sup>3</sup>Department of Neurosurgery, Queens Medical Centre, Nottingham, United Kingdom. <sup>4</sup>Division of Medical Sciences and Graduate Entry Medicine, Nottingham, United Kingdom

Paediatric Glioblastoma Multiforme (pGBM) is a lethal brain cancer with an average survival of 14 months. Due to the scarcity of effective treatment, pGBM forms the leading cause of CNS cancer death in children. Optune™ is a non-invasive therapy that uses alternating electric fields – coined TT fields - to disrupt cancer cell division, however it is not currently approved in children. Evidence shows that ion channels not only regulate electrical signalling of excitable cells, but also play a crucial role in the development and progression of brain tumours, essential in cell cycle control and therefore presenting as valuable therapeutic targets. Candidate ion channel genes (ICG) associated with the malignant status of high-grade glioma (HGG) were identified via multivariate analysis of in-house and publicly available data sets. RNA sequencing of in-house patient tissues revealed an increased expression of CLIC1 and CLIC4, with pHGG exhibiting increased expression at protein and RNA levels in both the Paugh data set and in-house primary cell lines and TMA. Clinical correlation determined that CLIC4 and CLIC1 deficiency was associated with increased overall survival ( $p < 0.03$ ). siRNA depletion of CLIC1 and CLIC4 propagated a reduction in the prolifer-

eration, migration and invasion of pHGG cell lines and resulted in cell cycle arrest. Furthermore, CLIC1 and CLIC4 deficiency exacerbated the killing capacity of TT fields. Whole transcriptome gene expression analysis (Human Clairom™ Array) of paediatric GBM cell lines treated with tumour treating fields and found that cells treated with TT fields exhibited a down-regulation in CLIC1 and CLIC4 compared to untreated cells. These data provide rationale that genetic, electrical, and pharmacological manipulation of ion channels will reduce the capacity of childhood brain tumours to proliferate and invade. Therefore, may be a suitable target for combination therapy to enhance the treatment efficacy of TT fields and help bring this non-invasive therapy to paediatric patients.

#### HGG-29. HOW I TREAT RECURRENT PEDIATRIC HIGH-GRADE GLIOMA (HGG): A EUROPE-WIDE SURVEY STUDY.

Thomas Perwein<sup>1</sup>, Barbara Giese<sup>1</sup>, Gunther Nussbaumer<sup>1</sup>, Adrés O. von Bueren<sup>2,3</sup>, Miriam van Buijen<sup>4</sup>, Martin Benesch<sup>1</sup>, Christof Maria Kramm<sup>5</sup>; <sup>1</sup>Division of Pediatric Hemato-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria. <sup>2</sup>Department of Pediatrics, Obstetrics and Gynecology, Division of Pediatric Hematology and Oncology, University Hospital of Geneva, Geneva, Switzerland. <sup>3</sup>Cansearch Research platform for pediatric oncology and hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland. <sup>4</sup>Department of Pediatric Hematology and Oncology, Center for Pediatrics, Medical Center-University of Freiburg, Freiburg, Germany. <sup>5</sup>Division of Pediatric Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany

**PURPOSE:** Prognosis of pediatric high-grade gliomas (pedHGG) is dismal, and there is no standard of care treatment in case of recurrence/progression. We aimed to gain an overview of different treatment strategies in the setting of recurrent/progressing pedHGG. **METHODS:** In a web-based questionnaire, members of the SIOPE-BTG and the GPOH were surveyed on different therapeutic options in four real-world case scenarios (children/adolescents with recurrent/progressing HGG). **RESULTS:** One hundred and thirty-nine clinicians with experience in pediatric neuro-oncology from 22 European countries participated in the survey. Most respondents preferred further active (multimodal) oncological treatment in three out of four cases and chose palliative care with pure symptom control measures only in one case (gliomatosis cerebri and marked symptoms). Depending on the case, 8-92% of experts would initiate a re-resection (maximal safe resection in case of localized hemispheric pedHGG), combined with molecular diagnostics, and 55-77% recommended (re-)irradiation, preferably local radiotherapy >20 Gy (or craniospinal irradiation in one case with disseminated spinal HGG, 65%). Throughout all case scenarios, most respondents would participate in clinical trials and use targeted therapy (79-99%), depending on molecular genetic findings (BRAF alterations: BRAF/MEK inhibitors, 64-88%; EGFR overexpression: anti-EGFR treatment, 46%; SMARCB1 deletion: EZH2 inhibitor, 12%). 31-72% would administer chemotherapy (CCNU, 17%; PCV, 8%; temozolomide, 19%; oral etoposide/trofosfamide, 8%), and 20-69% advocated immunotherapy (checkpoint inhibitors, 30%; tumor vaccines, 16%). Depending on the individual case, respondents would also include bevacizumab (6-18%), HDAC inhibitors (4-15%), tumor-treating fields (1-26%), and intraventricular chemotherapy (4-24%). **CONCLUSIONS:** In each case, experts would combine conventional multimodal treatment concepts, including re-irradiation, with targeted therapy based on molecular genetic findings. International cooperative trials combining a standard (chemo-)therapy backbone with targeted therapy approaches for defined subgroups may help to gain valid clinical data and improve treatment in pediatric patients with recurrent/progressive HGG.

#### HGG-30. H3.3 G34R/V MUTATIONS DISRUPT H3.3 MITOTIC PHOSPHORYLATION LEADING TO HIGH-GRADE GLIOMA FORMATION THROUGH THE INDUCTION OF CHROMOSOMAL INSTABILITY

Charles Day<sup>1,2</sup>, Florina Grigore<sup>1,3</sup>, Faruk Hakkim<sup>1</sup>, Alyssa Langfald<sup>1</sup>, Edward Hinchcliffe<sup>1,3</sup>, James Robinson<sup>1,3</sup>; <sup>1</sup>Hormel Institute - University of Minnesota, Austin, MN, USA. <sup>2</sup>Mayo Clinic, Rochester, MN, USA. <sup>3</sup>Masonic Cancer Center - University of Minnesota, Minneapolis, MN, USA

Pediatric high-grade gliomas (pHGG) are among the most lethal of all human cancers. Histone H3.3 G34R/V mutations are an early event in these tumors and show reduced H3.3 K36 trimethylation; implicating epigenetic dysregulation in tumorigenesis. Here we present evidence that H3.3 G34R/V mutations promote tumor formation via the induction of chromosomal instability (CIN). Pericentromeric H3.3 is phosphorylated at S31 by Chk1 during mitosis. We observed that the H3.3 G34R mutation reduced Chk1 phosphorylation of H3.3 S31 by >90% in vitro. Furthermore, H3.3 G34 mutant cells have reduced pericentromeric H3.3 S31 phosphorylation in mitosis compared to WT H3.3 cell lines. H3.3 G34 mutant pHGG cells also have significantly

elevated rates of CIN as compared to H3.3 WT cells. Overexpression of H3.3 G34R, G34V or non-phosphorylatable S31A in H3.3 WT, diploid cells caused a significant increase in CIN, but H3.3 K36M overexpression had no effect on chromosome segregation. These studies demonstrate that H3.3 G34R/V mutations are sufficient to induce CIN in normal, diploid cells. To determine if this process contributes to tumorigenesis, we used RCAS Nestin-TVA mice to overexpress H3.3 WT, G34R, or S31A - P2A-linked to PDGFB in glial precursor cells of newborn mice. Over 100 days, S31A and G34R mice had drastically reduced survival (averaging 77, 81, and 100 days for S31A, G34R, and WT). Furthermore, most G34R and S31A mice developed HGG, while H3.3 WT mice remained tumor-free. Our work implicates CIN as a driver of H3.3 G34 mutant pHGG formation.

#### HGG-31. UNIQUE CASE OF A BITHALAMIC H3K27-WILDTYPE DIFFUSE MIDLINE GLIOMA, EGFR-ALTERED WITH METHYLATED MGMT

James Reinecke<sup>1</sup>, Catherine Cottrell<sup>1,2</sup>, Sarah Rush<sup>3</sup>, Alexis Judd<sup>3</sup>, Joshua Palmer<sup>4</sup>, Christopher Pierson<sup>1,2</sup>, Margot Lazow<sup>1,2</sup>, Yelena Wilson<sup>3</sup>; <sup>1</sup>Nationwide Children's Hospital, Columbus, OH, USA. <sup>2</sup>The Ohio State University College of Medicine, Columbus, OH, USA. <sup>3</sup>Akron Children's Hospital, Akron, OH, USA. <sup>4</sup>The James Cancer Hospital at The Ohio State University, Columbus, OH, USA

**BACKGROUND:** Diffuse midline gliomas are aggressive pediatric brain tumors frequently associated with somatic mutations in histone genes *H3F3A* (H3.3) and *HIST1H3B* (H3.1), which promote gliomagenesis through reprogramming of the epigenetic landscape by inhibiting the tri-methylation of H3K27 (H3K27-me3). H3K27M-mutant gliomas comprise over 80% of diffuse midline gliomas, and are characterized by dismal outcomes as well as near-ubiquitous absence of MGMT promoter methylation. The subset of H3K27-wildtype diffuse midline gliomas remains incompletely understood with regards to underlying pathogenesis, therapeutic targets, and prognosis. We present the clinical, imaging, histopathologic, and molecular characteristics of a pediatric patient with a bithalamic H3K27-wildtype diffuse midline glioma, EGFR-altered with methylated MGMT. **CASE:** A 10-year-old female presented with an infiltrative bithalamic T2-hyperintense mass lacking diffusion restriction or contrast enhancement on MRI. Initial pathological inspection from biopsy was consistent with high-grade neuroepithelial tumor favoring high-grade glioma, however, immunohistochemistry was negative for H3K27M and demonstrated reduced H3K27-me3. DNA sequencing uncovered mutations in *EGFR* (exon 20 insertion) and *TP53* (R175H), with overexpression of *EGFR* and *CDK6* (but not *EZH2*) identified by RNA-sequencing. Methylation profiling was consistent with high-grade glioma, matching closest with glioblastoma, IDH-wildtype, with positive MGMT promoter methylation. Treatment was initiated with focal chemoradiotherapy with concurrent temozolomide, with plans for adjuvant temozolomide/ lomustine. **DISCUSSION:** Our case adds to growing evidence suggesting bithalamic tumors represent a distinct genetic and epigenetic subset of diffuse midline gliomas often defined by H3K27-wildtype status, loss of H3K27-me3, and EGFR receptor alterations. Our patient's H3K27-wildtype, EGFR-altered tumor had reduced H3K27-me3 as well as positive MGMT promoter methylation, a molecular characteristic that has not been well-studied in H3K27-wildtype bithalamic gliomas, but is suspected to confer sensitivity to alkylating chemotherapy. The prevalence, prognostic impact, and therapeutic implications of MGMT promoter methylation in bithalamic H3K27-wildtype diffuse midline gliomas, including potential association with EGFR aberrations, requires further exploration.

#### HGG-32. DURABLE RESPONSE TO MTOR INHIBITOR AFTER FAILING CHECKPOINT INHIBITORS IN ULTRA-HYPERMUTATED HIGH GRADE GLIOMA IN CONTEXT OF CMMRD

Kriti Hegde<sup>1</sup>, Christine Dahl<sup>1</sup>, Sarita Depani<sup>1</sup>, Darren Hargrave<sup>1</sup>, Minou Oostveen<sup>1</sup>, Fernando Aguirregomezcorra<sup>1</sup>, Owase Jeelani<sup>1</sup>, Kristian Aquilina<sup>1</sup>, Jenny Gains<sup>2</sup>, Yen Ching<sup>2</sup>, Thomas Jacues<sup>3</sup>, Ashirwad Merve<sup>3</sup>, Jane Chalker<sup>1</sup>, Dilys Addy<sup>1</sup>, Saira W. Ahmed<sup>3</sup>, Shireen Yasin<sup>3</sup>, Kshitij Mankad<sup>1</sup>, Olivia Carney<sup>1</sup>, Sniya Sudhakar<sup>1</sup>, Felice D'Arco<sup>1</sup>, Ulrike Loebel<sup>1</sup>, Mette Jorgensen<sup>1</sup>; <sup>1</sup>Great Ormond Street Hospital, London, England, United Kingdom. <sup>2</sup>University College London Hospital, London, England, United Kingdom. <sup>3</sup>DBC Department, UCL GOS Institute of Child Health and Department of Histopathology, GOSH, London, England, United Kingdom

**BACKGROUND:** Paediatric High Grade Gliomas (HGG) have poor outcomes with conventional treatment. HGG in association with constitutional DNA mismatch repair deficiency (CMMRD) are hypermutated and have shown dramatic response to checkpoint inhibitors. Salvage following progression or failure to respond to checkpoint inhibitors has rarely been reported. We describe a successful alternative therapeutic approach targeting the activated pathway (mTOR) in a hypermutated HGG. **CASE SUMMARY:** A 6-year-old girl presenting with seizures was diagnosed with left frontal lobe HGG with concurrent neck mass (Pilomatixoma). Presence of synchronous tumours raised the